Compare Allegion PLC (ALLE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs Merck & Co., Inc. — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Merck & Co., Inc. trades at $123.56 (market cap $305.12B). The key difference: Merck & Co., Inc. is far larger — about 26× Allegion PLC's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| ALLE | MRK | |
|---|---|---|
Market Cap | $11.74B | $305.12B |
Sector | Industrials | Health |
52-Week High | $179.77 | $129.52 |
52-Week Low | $125.65 | $77.60 |
Enterprise Value | $13.46B | $348.54B |
Dividend Yield | 1.55% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, including Q1 2026, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives amid a competitive pharmaceutical landscape.
The stock presents a favorable risk-reward profile with upside potential driven by earnings momentum and strategic acquisitions, though risks include patent expirations and regulatory pressures. Institutional buying activity and a 67.57% buy rating from analysts underscore confidence, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
